Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Helicobacter Pylori Infection
Interventions: Amoxicillin, Omeprazole, Clarithromycin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Painful Diabetic Neuropathy
Interventions: Flowaid FA-100 SCCD; Device
Lead sponsor: Rosenblum, Jonathan I., DPM; Individual
Eligibility: 18 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lodi, New Jersey

Conditions: Mild Traumatic Brain Injury, Concussion Post Syndrome
Interventions: Psychological Intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anxiety Disorders, Mood Disorders
Interventions: Single Diagnosis Treatment Protocol, Unified Protocol (UP); Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Anesthesia, Local, Phrenic Nerve Paralysis, Upper Extremity Injury, Phrenic Nerve Palsy on the Left, Phrenic Nerve Palsy on the Right
Interventions: Normal saline injected via interscalene nerve catheter, Placebo; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: COVID, Coronavirus, COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Labor Dystocia, Labor Induction, Labor Augmentation
Interventions: Calcium Carbonate 500 MG, Standard Dose Synthetic Pitocin; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Upper Extremity Hemiplegia, Stroke
Interventions: Contralaterally Controlled Functional Electrical Stimulation (CCFES), Hand Therapy Video Games; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cardiogenic Shock, Heart Failure, Inflammation
Interventions: Methylprednisone, Standard of Care (SOC); Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions: Placebo, Enicepatide; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more

Conditions: Hidradenitis Suppurativa
Interventions: Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more

Conditions: Non Small Cell Lung Cancer
Interventions: quaratusugene ozeplasmid, pembrolizumab, docetaxel, ramucirumab, Investigator's Treatment of Choice; Biological · Drug
Lead sponsor: Genprex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Tampa, Florida • New Orleans, Louisiana • St Louis, Missouri + 3 more

Conditions: Diabetes Mellitus Type 2
Interventions: aleglitazar+metformin, placebo+metformin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 22
States / cities: Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more

Conditions: Hemophilia A With Inhibitors
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Pain, Acute, Nausea, Vomiting, Postoperative, Opioid Use, Satisfaction
Interventions: Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline, Enhanced recovery after breast surgery (ERABS) strategies, Sham paravertebral block using saline, Paravertebral block using local anesthetic; Procedure · Other · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Matching Placebo, Verdiperstat; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 12
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more

Conditions: Plaque, Dental, Gingivitis
Interventions: Test regimen, Control regimen; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Atrial Fibrillation
Interventions: Ablation; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Ulcerative Colitis
Interventions: Budesonide MMX®, Placebo, 5-ASA; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 39
States / cities: Anaheim, California • Lakewood, California • San Diego, California + 36 more

Conditions: Traumatic Brain Injury
Interventions: Ketogenic Diet; Other
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 2 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Search by objective public record fields.

High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population

An Evaluation of an SCCD on the Symptomatology of Painful DPN

Treatment for Patients With Chronic Post-Concussion Symptoms

Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Interscalene Brachial Plexus Block Washout to Reverse Inadvertent Phrenic Nerve Blockade

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

Calcium Carbonate to Augment Labor Contractions

Contralaterally Controlled Functional Electrical Stimulation Plus Video Games for Hand Therapy After Stroke

CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Enhanced Recovery Strategies in Elective Breast Surgery

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

HEALEY ALS Platform Trial - Regimen B Verdiperstat

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Clinical Investigation to Assess the Efficacy of Manual Toothbrushes in the Reduction of Plaque and Gingivitis.

Strategies in Patients Undergoing Repeat AF Ablation

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Ketogenic Diet Following Moderate to Severe Pediatric Traumatic Brain Injury